| 1 | 1 | | By: Toth H.B. No. 967 |
|---|
| 2 | 2 | | |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | |
|---|
| 6 | 6 | | A BILL TO BE ENTITLED |
|---|
| 7 | 7 | | AN ACT |
|---|
| 8 | 8 | | relating to a study on the prevalence of the use of psychoactive or |
|---|
| 9 | 9 | | psychotropic medication by persons who have committed suicide. |
|---|
| 10 | 10 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 11 | 11 | | SECTION 1. (a) In this Act: |
|---|
| 12 | 12 | | (1) "Commission" means the Health and Human Services |
|---|
| 13 | 13 | | Commission. |
|---|
| 14 | 14 | | (2) "Psychoactive medication" has the meaning |
|---|
| 15 | 15 | | assigned by Section 242.505, Health and Safety Code. |
|---|
| 16 | 16 | | (3) "Psychotropic medication" has the meaning |
|---|
| 17 | 17 | | assigned by Section 266.001, Family Code. |
|---|
| 18 | 18 | | (b) The commission shall conduct a study evaluating the |
|---|
| 19 | 19 | | prevalence of the use of psychoactive or psychotropic medication by |
|---|
| 20 | 20 | | persons who are reported to have committed suicide. The study must |
|---|
| 21 | 21 | | evaluate: |
|---|
| 22 | 22 | | (1) for persons for whom a report described by |
|---|
| 23 | 23 | | Subsection (c) indicated the use of psychoactive or psychotropic |
|---|
| 24 | 24 | | medication: |
|---|
| 25 | 25 | | (A) the period of time the person was taking |
|---|
| 26 | 26 | | psychoactive or psychotropic medication; |
|---|
| 27 | 27 | | (B) the medication the person was taking; |
|---|
| 28 | 28 | | (C) whether there is evidence of the person |
|---|
| 29 | 29 | | experiencing withdrawal symptoms; and |
|---|
| 30 | 30 | | (D) if applicable, the period of time the person |
|---|
| 31 | 31 | | was experiencing withdrawal symptoms; and |
|---|
| 32 | 32 | | (2) for persons for whom a report described by |
|---|
| 33 | 33 | | Subsection (c) did not indicate the use of psychoactive or |
|---|
| 34 | 34 | | psychotropic medication: |
|---|
| 35 | 35 | | (A) whether there is evidence of the person |
|---|
| 36 | 36 | | having recently discontinued using psychoactive or psychotropic |
|---|
| 37 | 37 | | medication; and |
|---|
| 38 | 38 | | (B) whether there is evidence of the person |
|---|
| 39 | 39 | | experiencing withdrawal symptoms. |
|---|
| 40 | 40 | | (c) In conducting the study, the commission shall use |
|---|
| 41 | 41 | | autopsy reports, toxicology reports, police reports, and other |
|---|
| 42 | 42 | | information related to persons who are reported to have committed |
|---|
| 43 | 43 | | suicide that are: |
|---|
| 44 | 44 | | (1) collected between January 1, 2016, to December 31, |
|---|
| 45 | 45 | | 2022; and |
|---|
| 46 | 46 | | (2) concerning persons who resided in counties with a |
|---|
| 47 | 47 | | population of 450,000 or more. |
|---|
| 48 | 48 | | (d) Not later than October 1, 2025, the commission shall |
|---|
| 49 | 49 | | prepare and submit to the governor, the lieutenant governor, and |
|---|
| 50 | 50 | | the speaker of the house of representatives a written report |
|---|
| 51 | 51 | | containing the results of the study. |
|---|
| 52 | 52 | | (e) The study required by this Act is a public record under |
|---|
| 53 | 53 | | Chapter 552, Government Code. |
|---|
| 54 | 54 | | (f) The commission shall comply with all applicable state |
|---|
| 55 | 55 | | and federal laws regarding personally identifiable information in |
|---|
| 56 | 56 | | conducting the study. |
|---|
| 57 | 57 | | SECTION 2. This Act takes effect September 1, 2025. |
|---|